Suárez GJA, Machado GM, Machado BHL, Bouza JD, González VK, Anoceto AE

Language: Spanish
References: 20
Page: 1-7
PDF size: 157.33 Kb.

ABSTRACT

Uterine sarcomas are a diverse group of tumors that make up 1% of the neoplasms of the female genital tract. The worldwide incidence is from 0.5 to 3.3 cases per 100,000 women per year. A rare case with a diagnosis of high-grade uterine leiomyosarcoma is presented and a review of the literature on this subject is made.

REFERENCES

1. Cárdenas-Serrano OE, Villalón-López JS, Ruiz-Mar G, Daza-Benítez L. Diagnóstico de sarcoma uterino, revisión de 11 casos. Ginecol Obstet Mex. 2015;83(9):515-21.

2. José Solis C. Sarcomas uterinos: manejo actual. Rev Chil Obstet Ginecol. 2005;70(5):332-9.

3. Pautier P, Genestie C, Rey A. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer. 2000;88(6):1425-31.

4. Martínez-Madrigal M, Muñoz-González DE, Ochoa-Carrillo FJ, Camacho-Beiza IR, García-Juárez E. Sarcoma Uterino: Revisión de la literatura. GAMO. 2012;2(11):113-7.

5. Iglesias Castañón A, Arias González M, Herreros Villaraviz M, Nieto Parga A, Nieto Baltar B, et al. Nueva clasificación de la FIGO en los sarcomas uterinos: ¿Qué ha cambiado? SERAM. 2014. Disponible en: https://posterng.netkey.at/esr/viewing/index.php?module=viewing_poster&task=&pi=1 23928

6. Giuntoli RL 2nd, Metzinger DS, DiMarco CS. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89(3):460-9.

7. Rha SE, Byun JY, Jung SE. CT and MRI of uterine sarcomas and their mimickers. AJR Am J Roentgenol. 2003 Nov;181(5):1369-74.

8. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137-50.

9. Major FJ, Blessing JA, Silverberg SG. Prognostic factors in earlystage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71:1702-9.

10. Pautier P, Genestie C, Rey A. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer. 2000;88(6):1425-31.

11. Giuntoli RL 2nd, Metzinger DS, DiMarco CS. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89(3):460-9.

12. Rha SE, Byun JY, Jung SE. CT and MRI of uterine sarcomas and their mimickers. AJR Am J Roentgenol. 2003;181:1369-74.

13. Verschraegen CF, Vasuratna A, Edwards C. Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. Oncol Rep. 1998;5(4):939-44.

14. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18(6):535-58.

15. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21(4):363-81.

16. Rha SE, Byun JY, Jung SE. CT and MRI of uterine sarcomas and their mimickers. AJR Am J Roentgenol. 2003 Nov;181(5):1369-74.

17. Huang GS, Chiu LG, Gebb JS. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol. 2007;107(3):513-7.

18. Peters WA 3rd, Bagley CM, Smith MR. CA-125 Use as a tumor marker with mixed mesodermal tumors of the female genital tract. Cancer. 1986;58(12):2625-7.

19. Oliva E, Clement PB, Young RH. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv Anat Pathol. 2000;7(5):257-81.

20. Leath CA 3rd, Huh WK, Hyde J Jr. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007;105(3):630-4.